Skip to main content
. 2020 Jun;61(6):897–903. doi: 10.2967/jnumed.119.235093

TABLE 2.

Number of Lesions Found on 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT

Primary tumor
Liver metastases
Bone metastases
Lymph node metastases
Rare metastases
Total lesions
Patient JR11 TATE JR11 TATE JR11 TATE JR11 TATE JR11 TATE JR11 TATE
1 1 1 13 4 3 15 2 3 19 23
2 1 1 11 11 3 3 15 15
3 1 1 34 34 2 1 37 36
4 0 6 1 1 1 7
5 1 1 14 12 15 13
6 1 1 3 1 4 2
7 7 2 7 2
8 13 3 2 1 15 4
9 2 5 0 10* 2 5 4 20
10 2 2 46 46 12 12 1 1 61 61
11 1 1 1 0 2 1
12 1 1 64 43 65 44
13 1 1 29 13 2 1 32 15
14 1 1 16 2 17 3
15 1 1 6 6 3 1 10 8
16 54 27 54 27
17 1 1 48 48 49 49
18 16 16 16 16
19 3 8 6 9 9 17
20 1 1 36 36 37 37
21 39 46 5 5 51 51 95 102
22 1 1 1 1
23 1 1 17 17 14 192 3 3 2 2 37 215
24 0 1 3 3 3 4
25 6 0 6 0
26 1 1 69 22 85 85 9§ 2§ 164 110
27 1 1 21 1 22 2
28 1 1 5 5 3 3 9 9
29 12 6 1 1 13 7
30 0 1 2 2 2 14 1 1 5 18
31 11 7 11 7
Sum 20 24 552 365 158 388 43 43 62 55 835 875
P 0.500 0.001 0.016 0.727 0.152
*

Patient 9 had heterogeneous diffuse osseous uptake of 68Ga-DOTATATE. We arbitrarily set number of osseous lesions to be 10.

Pleural metastases.

Peritoneal metastases.

§

Splenic metastases.